UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will deliver a fireside chat presentation on Wednesday, April 9, 2025, at 8:45 a.m. ET.
Investors and interested parties can access the live webcast through the 'Investors' section of Liquidia's website. A recorded version of the presentation will remain available on the company's website for a minimum of 30 days after the event.
Liquidia (NASDAQ: LQDA), un'azienda biofarmaceutica focalizzata sulle terapie per malattie cardiopolmonari rare, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. L'azienda presenterà un intervento in forma di chiacchierata informale mercoledì 9 aprile 2025, alle 8:45 a.m. ET.
Gli investitori e le parti interessate possono accedere alla diretta del webcast attraverso la sezione 'Investitori' del sito web di Liquidia. Una registrazione della presentazione rimarrà disponibile sul sito dell'azienda per un minimo di 30 giorni dopo l'evento.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica enfocada en terapias para enfermedades cardiopulmonares raras, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Atención Médica de Needham. La empresa realizará una presentación en forma de charla informal el miércoles 9 de abril de 2025, a las 8:45 a.m. ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Inversores' del sitio web de Liquidia. Una versión grabada de la presentación estará disponible en el sitio web de la empresa durante un mínimo de 30 días después del evento.
Liquidia (NASDAQ: LQDA), 희귀 심폐 질환 치료에 중점을 둔 생물 제약 회사가 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다. 회사는 2025년 4월 9일 수요일 오전 8시 45분 ET에 화상 채팅 형식의 발표를 진행할 예정입니다.
투자자 및 관심 있는 당사자는 Liquidia 웹사이트의 '투자자' 섹션을 통해 생중계 웹캐스트에 접근할 수 있습니다. 발표의 녹화된 버전은 행사 후 최소 30일 동안 회사 웹사이트에서 이용 가능합니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur les thérapies pour les maladies cardiopulmonaires rares, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé. L'entreprise présentera une discussion informelle le mercredi 9 avril 2025, à 8h45 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section 'Investisseurs' du site Web de Liquidia. Une version enregistrée de la présentation restera disponible sur le site de l'entreprise pendant au moins 30 jours après l'événement.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene kardiopulmonale Erkrankungen spezialisiert hat, hat seine Teilnahme an der 24. jährlichen virtuellen Needham Gesundheitskonferenz angekündigt. Das Unternehmen wird am Mittwoch, den 9. April 2025, um 8:45 Uhr ET eine informelle Gesprächsrunde präsentieren.
Investoren und Interessierte können über den Bereich 'Investoren' auf der Website von Liquidia auf den Live-Webcast zugreifen. Eine aufgezeichnete Version der Präsentation bleibt mindestens 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar.
- None.
- None.
MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET.
Access to a webcast of the presentation will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia (LQDA) presenting at the Needham Healthcare Conference 2025?
How can investors access Liquidia's (LQDA) Needham Conference presentation?
How long will LQDA's Needham Conference presentation recording be available?
What is the focus area of Liquidia (LQDA)?
